

CITATION REPORT

List of articles citing

Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial

DOI: 10.1016/s0735-1097(03)00241-9

Journal of the American College of Cardiology, 2003, 41, 1438-44.

Source: <https://exaly.com/paper-pdf/35369703/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
454	Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?. 2003 , 42, 1301-4		2
453	Erythropoietin should be part of congestive heart failure management. 2003 , S40-7		27
452	Highlights of the year in JACC 2003. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 2156-66	15.1	0
451	Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. 2003 , 9, 429-43		50
450	Carvedilol: a review of its use in chronic heart failure. 2003 , 63, 1697-741		45
449	How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. 2003 , 14, 2556-72		65
448	Predictors of stable outcome in treating chronic heart failure patients with carvedilol. 2004 , 45, 823-32		4
447	Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. 2004 , 15, 435-41		82
446	beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. 2004 , 164, 2465-71		87
445	Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. 2004 , 15, 2902-7		57
444	Atherosclerosis in dialyzed patients. 2004 , 22, 28-37		23
443	Sympathetic hyperactivity in chronic renal failure: a wake-up call. 2004 , 15, 524-37		164
442	Sympathetic hyperactivity in chronic kidney disease. 2004 , 19, 1354-7		40
441	Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial. <i>European Journal of Heart Failure</i> , 2004 , 6, 787-91	12.3	16
440	Causes and consequences of increased sympathetic activity in renal disease. 2004 , 43, 699-706		138
439	Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. 2004 , 65, 1568-76		199
438	How can the poor outcomes for diabetic dialysis patients be improved?. 2004 , 17, 186-7		1

437	How can the poor outcomes for diabetic dialysis patients be improved?. 2004 , 17, 188-90		
436	How can the poor outcomes for diabetic dialysis patients be improved?. 2004 , 17, 190-1		
435	How can the poor outcomes for diabetic dialysis patients be improved?. 2004 , 17, 191-3		
434	How can the poor outcomes for diabetic dialysis patients be improved?. 2004 , 17, 194-5		2
433	Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications. 2004 , 17, 265-9		21
432	Drug therapy for hypertension in hemodialysis patients. 2004 , 17, 288-94		25
431	Cardiac consequences of hypertension in hemodialysis patients. 2004 , 17, 299-303		31
430	Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists. 2004 , 44, 309-21		4
429	Treating the Patient with Kidney Failure to Reduce Cardiovascular Disease Risk. 2004 , 6, 257-268		1
428	Optimal dialysis for the end-stage renal disease patient with cardiovascular disease. 2004 , 11, 261-73		3
427	Cardiovascular risk in stage 4 and 5 nephropathy. 2004 , 11, 116-33		23
426	Opportunities for improvement in the cardiovascular care of patients with end-stage renal disease. 2004 , 11, 294-303		8
425	The association between congestive heart failure and chronic renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 163-70	3.5	98
424	Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 591-600	3.5	44
423	Current World Literature. <i>Current Opinion in Nephrology and Hypertension</i> , 2005 , 14, 604-625	3.5	
422	The clinical epidemiology of cardiovascular disease in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2005 , 14, 550-7	3.5	24
421	Hypertension in dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2005 , 14, 111-8	3.5	10
420	Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: A National Veterans Administration study[1]. 2005 , 68, 826-832		19

419	Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. 2005 , 68, 1419-26	9
418	Evaluation and treatment of coronary artery disease in patients with end-stage renal disease. 2005 , S51-8	14
417	Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. 2005 , 38, 243-57	87
416	K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. 2005 , 45, 16-153	184
415	Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. 2005 , 25, 211-20	32
414	Hemodialysis--from early days to tomorrow. 2005 , 149, 1-9	5
413	Pathophysiology of cardiovascular disease and renal failure. 2005 , 23, 311-7	18
412	Cardiovascular risk in chronic renal disease and transplantation prevention and management. 2005 , 6, 929-43	6
411	The role of the kidney in cardiovascular medicine. 2005 , 16, 321-7	7
410	Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1051-60 ^{15.1}	179
409	Are there clinically important differences between beta-blockers in heart failure?. 2005 , 1, 57-66	1
408	Cardioprotective medication use in hemodialysis patients. 2006 , 22, 755-60	36
407	Renal impairment: a risk factor for ischemic heart disease. 2006 , 6, 221-5	3
406	Kidney disease in cardiology. 2007 , 22, 43-6	7
405	Cardiovascular effects of a phosphodiesterase III inhibitor in the presence of carvedilol in dogs. 2006 , 68, 549-53	4
404	How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis?. 2006 , 19, 8-24	
403	Opinion: How Should Chronic Medical Therapies be Altered with the Onset of End-Stage Renal Disease and Initiation of Dialysis?. 2006 , 19, 17-20	
402	Beta blockers in the management of chronic kidney disease. 2006 , 70, 1905-13	134

401	The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. 2006 , 70, 2021-30	163
400	Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. 2006 , 38, 295-310	86
399	Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure. 2006 , 449, 207-14	10
398	Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. 2006 , 48, 341-60	62
397	Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. 2006 , 48, 645-51	23
396	The challenge of the unacceptable high mortality in end-stage kidney disease: is folic acid the answer?. 2006 , 24, 377-8	1
395	Cause and consequences of sympathetic hyperactivity in chronic kidney disease. 2006 , 24, 95-9	31
394	Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. 2007 , 22, 59-63	11
393	Kidney-heart interactions: epidemiology, pathogenesis, and treatment. 2006 , 1, 8-18	133
392	Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. 2006 , 1, 193-208	44
391	The Diabetic Kidney. 2006 ,	1
390	Kidney disease and cardiovascular risk. 2007 , 58, 123-39	54
389	Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?. 2007 , 18, 2377-84	85
388	Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. 2007 , 49, 506-10	87
387	Is the declining use of long-term peritoneal dialysis justified by outcome data?. 2007 , 2, 1317-28	56
386	Can we prevent sudden cardiac death in dialysis patients?. 2007 , 2, 410-2	30
385	Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. 2008 , 23, 56-61	10
384	Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. 2007 , 27, 7-14	24

383	Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. 2007 , 72, 1527-34	14
382	Novel adjunct to surgery for end-stage cardiomyopathy receiving hemodialysis. 2008 , 7, 272-4	1
381	Non-cardiac comorbidities in chronic heart failure. 2007 , 93, 665-71	76
380	Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. 2007 , 2, 1186-90	57
379	Automated external defibrillators and survival from cardiac arrest in the outpatient hemodialysis clinic. 2007 , 18, 312-20	43
378	Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. 2007 , 2, 491-500	78
377	Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. 2007 , 30, 2146-53	26
376	Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. 2007 , 30, 537-42	34
375	Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker. 2007 , 49, 191-6	12
374	Carvedilol: use in chronic heart failure. 2007 , 5, 21-31	23
373	[Drug treatment of hypertension in hemodialysed patients]. 2007 , 3 Suppl 3, S185-90	
372	The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis. 2007 , 17, 243-9	23
371	Should beta-blockers be used to control hypertension in people with chronic kidney disease?. 2007 , 27, 555-64	28
370	[Importance of the study of renal function in cardiology]. 2007 , 128, 705-10	0
369	Cardiorenal syndrome at different stages of chronic kidney disease. 2007 , 30, 564-76	9
368	Inadequate treatment of congestive heart failure in dialysis patients. 2007 , 20, 383-6	7
367	Cardiovascular risk profile assessment and medication control should come first. 2007 , 20, 405-8	0
366	Hypertension is harmful to dialysis patients and should be controlled. 2007 , 20, 518-22	9

365	Beta-blockade in chronic dialysis patients. 2008 , 21, 43-8	26
364	Dialysis, cardiovascular disease, and the future. 2007 , 11, S2-S11	5
363	Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. 2007 , 11, 1-14	51
362	Which issues should trials address in hemodialysis?. 2007 , 11, S44-S47	
361	Cardiovascular complications of chronic kidney disease. 2007 , 35, 453-456	2
360	Anticoagulation for chronic atrial fibrillation in hemodialysis patients: which fruit from the decision tree?. 2007 , 50, 345-8	9
359	Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?. 2007 , 9, 409-14	7
358	Sudden cardiac death and dialysis patients. 2008 , 21, 300-7	204
357	Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients. 2008 , 21, 326-30	27
356	Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients. 2008 , 38, 361-4	3
355	Cardiovascular Death in Uremia More Complex Than We Thought. 2008 , 10, 7-13	
354	Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardiorenal syndrome. 2008 , 8, 2219-24	46
353	Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review. 2008 , 128, 154-65	9
352	The effectiveness of renal transplantation as a treatment for recurrent uremic cardiomyopathy. 2008 , 24, 315-7	5
351	Treatment of hypertension in heart failure with preserved ejection fraction: role of the kidney. 2008 , 4, 479-503	
350	Management of ischemic heart disease in patients with chronic kidney disease. 2008 , 8, 219-31	1
349	Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias. 2008 , 30, 701-9	66
348	Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels. 2008 , 30, 357-62	6

347	Beta-blockers for coronary heart disease in chronic kidney disease. 2008 , 23, 2274-9	17
346	Should nephrologists use beta-blockers? A perspective. 2009 , 24, 701-2	13
345	Negative outcome studies in end-stage renal disease. 2008 , 26, 63-6	6
344	Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease: Ischaemic heart disease. 2008 , 94, 1080-8	13
343	Left ventricular dysfunction in the haemodialysis population. <i>CKJ: Clinical Kidney Journal</i> , 2008 , 1, 199-205	12
342	The challenge of sudden death in dialysis patients. 2008 , 3, 920-9	89
341	Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. 2008 , 3, 79-88	22
340	Evaluation of vascular calcifications in CKD patients. 2009 , 32, 81-6	4
339	Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. 2009 , 113, c132-9	17
338	Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. 2009 , 53, 860-6	153
337	The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. 2009 , 30, 1559-64	26
336	Decreased pulse pressure during hemodialysis is associated with improved 6-month outcomes. 2009 , 76, 1098-107	37
335	Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. 2009 , 24, 2809-16	47
334	Sympathetic activation in chronic renal failure. 2009 , 20, 933-9	314
333	Left ventricular mass in chronic kidney disease and ESRD. 2009 , 4 Suppl 1, S79-91	225
332	Optimal cardiovascular therapy for patients with ESRD over the next several years. 2009 , 4 Suppl 1, S106-9	7
331	[Heart rate variability alteration in patients on chronic hemodialysis]. 2009 , 58, 7-10	
330	The ABCs of cardioprotection in dialysis patients: a systematic review. 2009 , 53, 457-66	29

329	Patterns of cardioprotective medication prescription in incident hemodialysis patients. 2009 , 41, 1021-7	7
328	Pharmacologic management of the cardiorenal syndrome in heart failure. 2009 , 6, 105-11	15
327	Medication changes based on echocardiography in dialysis patients. 2009 , 13, 472-8	0
326	Conservative treatment of the uremic syndrome. 2009 , 22, 449-53	1
325	The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). 2009 , 15, 310-8	66
324	Hypertension in hemodialysis patients: the role of antihypertensive medications. 2009 , 54, 996-9	2
323	Cardiac function in an African dialysis population with a low prevalence of pre-existing cardiovascular disease. 2009 , 31, 211-20	2
322	Hypertension in dialysis and kidney transplant patients. 2009 , 25, 309-14	19
321	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. 2009 , 373, 1009-15	302
320	Prevention of cardiovascular disease in chronic kidney disease patients. 2009 , 29, 24-9	5
319	End-Stage Renal Disease and Sudden Cardiac Death. 2009 , 1, 61-77	3
318	Beta-blockers for coronary heart disease in chronic kidney disease. 2009 , 2009, 272-273	
317	Hyperhomocysteinemia and sudden cardiac death: potential arrhythmogenic mechanisms. <i>Current Vascular Pharmacology</i> , 2010 , 8, 64-74	3,3 18
316	The heart and diabetic nephropathy. 2010 , 6, 9-14	1
315	Hypertension in Hemodialysis Patients. 2010 , 6, 44-54	1
314	Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. 2010 , 74, 1578-83	13
313	The use of H1-receptor antagonists and left ventricular remodeling in patients on chronic hemodialysis. 2010 , 25, 163-9	7
312	The management of diabetic neuropathy in CKD. 2010 , 55, 365-85	37

311	Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. 2010 , 106, 402-8		44
310	Increased Left Ventricular Mass in Chronic Kidney Disease and End-Stage Renal Disease: What Are the Implications?. 2010 , 39, 16-19		5
309	Management of Comorbidity in Chronic Heart Failure. 2010 , 137-156		
308	Antihypertensive agents in hemodialysis patients: a current perspective. 2010 , 23, 290-7		56
307	Cardiovascular complications in diabetic kidney disease. 2010 , 23, 169-77		13
306	Avalia e manejo da doen cardiovascular em pacientes com doen renal crica. 2010 , 32, 120-127		5
305	Cardiovascular Disease in Chronic Kidney Disease. 2010 , 935-950		4
304	Cardiovascular Disease in Patients with Chronic Kidney Disease. 2010 , 128-144		1
303	Sudden death in hemodialysis: an update. 2010 , 30, 135-45		33
302	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 607-16	12.3	50
301	Can we reduce the cardiovascular risk in peritoneal dialysis patients?. 2010 , 20, 59-67		13
300	Comorbidities in Heart Failure. 2010 , 257-270		1
299	Management of chronic cardiorenal syndrome. 2010 , 165, 129-139		6
298	Hypertension in end-stage renal disease: different measures and their prognostic significance. 2010 , 25, 3161-6		10
297	Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. 2010 , 122, 25-34		23
296	Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1701-8	15.1	132
295	Treating heart failure on dialysis. Finally getting some evidence. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1709-11	15.1	3
294	Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. 2010 , 77, 273-84		125

293	Ventricular arrhythmias and sudden death in patients with chronic kidney disease. 2010 , 36 Suppl 1, 54-60	7
292	The growing problem of intradialytic hypertension. 2010 , 6, 41-8	25
291	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. 2010 , 25, 2077-89	24
290	Sudden cardiac death in chronic kidney disease: epidemiology and prevention. 2011 , 7, 145-54	93
289	Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 2011 , 80, 572-86	54 ^o
288	Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1152-61	15.1 111
287	Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. 2011 , 79, 218-27	174
286	The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. 2011 , 27, 319-38	123
285	Renal dysfunction prevalence and clinical impact in heart failure. 2011 , 99	
284	Prevenire la morte improvvisa nel paziente uremico: mission impossible per cardionefrologi?. 2011 , 23, 69-74	
283	Role of Implantable Cardioverter Defibrillators for Dialysis Patients. 2011 ,	
282	A perfect cardiomyopathic storm. 2011 , 24, 278-9	1
281	Predisposition to arrhythmias: electrolytes, uremic fibrosis, other factors. 2011 , 24, 287-9	3
280	Treatment of heart failure in long-term dialysis patients: a reappraisal. 2011 , 57, 760-72	11
279	Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. 2011 , 58, 73-83	21
278	βBlockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. 2011 , 58, 939-45	27
277	Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. 2011 , 31, 218-39	67
276	End-stage renal disease: sudden cardiac death: stratifying risk in dialysis patients. 2011 , 7, 133-5	16

275	Sudden Cardiac Death & Dialysis: Target Risk Factors. 2011 , 4, 3-5	
274	Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. 2011 , 6, 2620-7	38
273	Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. 2011 , 6, 805-12	36
272	Sudden cardiac death in patients with chronic kidney disease: prevention is the sine qua non. 2011 , 34, 269-76	9
271	Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. 2011 , 4, 18-26	48
270	Microvolt T-wave alternans in end-stage renal disease patients--associations with uremic cardiomyopathy. 2011 , 6, 519-27	19
269	Tachycardia as a predictor of poor survival in chronic haemodialysis patients. 2011 , 26, 963-9	26
268	Survival trends of US dialysis patients with heart failure: 1995 to 2005. 2011 , 6, 1982-9	8
267	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. 2012 , 126, 617-63	181
266	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. 2012 , 27, 1591-8	16
265	Sudden cardiac death in hemodialysis patients: a comprehensive care approach to reduce risk. 2012 , 33, 183-9	24
264	Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes. 2012 , 90, 117-24	5
263	Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. 2012 , 2, 281-297	16
262	Conséquences cardiaques de l'insuffisance rénale chronique. 2012 , 9, 1-14	
261	End-stage renal disease and cardiomyopathy in children: cardiac effects of renal transplantation. 2012 , 93, 182-7	5
260	Elevated resting heart rate is an independent predictor of all-cause death and cardiovascular events in Japanese ambulatory hemodialysis patients. 2012 , 16, 938-44	5
259	Medical options to fight mortality in end-stage renal disease: a review of the literature. 2012 , 27, 4298-307	20
258	Challenges in blood pressure measurement in patients treated with maintenance hemodialysis. 2012 , 60, 463-72	12

257	Sudden cardiac death in dialysis: do current guidelines for implantable cardioverter defibrillator therapy apply to patients with end-stage kidney disease?. 2012 , 25, 272-6		6
256	Systematic review of noncancer presentations with a median survival of 6 months or less. 2012 , 125, 512.e1-6		39
255	Prevention of sudden cardiac death in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2012 , 13, 162	2.7	23
254	Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. <i>BMC Nephrology</i> , 2012 , 13, 167	2.7	16
253	Treatment of the Patient with End-Stage Diabetic Nephropathy. 2012 , 215-231		
252	Dialysis-dependent changes in ventricular repolarization. 2012 , 35, 703-10		8
251	Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. 2012 , 16, 387-435		77
250	Hemodialysis in diabetics end-stage renal disease. 2012 , 1, 163-165		
249	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 434-80	15.1	253
248	Hypertension in Chronic Kidney Disease. 2012 , 35-50		
247	Sub-Types and Therapeutic Management of the Cardiorenal Syndrome. 2012 ,		
246	Approach to cardiovascular disease prevention in patients with chronic kidney disease. 2012 , 14, 391-413		7
245	The intuitive case for Eblockers in patients with ESRD. 2012 , 25, 15-21		5
244	Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. 2012 , 59, 670-81		24
243	Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations. 2012 , 27, 339-50		21
242	Cardiovascular disease in chronic kidney disease: untying the Gordian knot. 2013 , 67, 14-31		37
241	Management of cardiovascular disease in patients with kidney disease. 2013 , 10, 261-73		74
240	Pharmacologic management of chronic reno-cardiac syndrome. 2013 , 10, 54-62		11

239	β-blocker prevents sudden cardiac death in patients with hemodialysis. 2013 , 165, 519-22	19
238	[Fluid overload and arterial hypertension in hemodialysis patients]. 2013 , 9, 408-15	3
237	Pharmacologic treatment of hypertension in patients with chronic kidney disease. 2013 , 13, 177-88	6
236	Blood pressure and blood volume: acute and chronic considerations in hemodialysis. 2013 , 26, 62-72	9
235	The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes. 2013 , 39, 290-8	26
234	Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. 2013 , 26, 333-43	59
233	Management of coronary atherosclerosis and acute coronary syndromes in patients with chronic kidney disease. 2013 , 38, 165-206	9
232	The sympathetic nervous system in chronic kidney disease. 2013 , 15, 370-6	18
231	Echocardiographical determinants of an abnormal spatial QRS-T angle in chronic dialysis patients. 2013 , 28, 3045-52	5
230	Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. 2013 , 28, 1579-89	75
229	Evidence-based cardiology in hemodialysis patients. 2013 , 24, 1934-43	36
228	Echocardiography: Providing additional insights into cardiovascular structural and functional abnormalities in advanced CKD. 2013 , 8, 339-41	3
227	Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients. 2013 , 2, e000091	21
226	Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. 2013 , 8, 2106-16	50
225	Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure. 2013 , 123-135	
224	Prevention of sudden cardiac death in dialysis patients: drugs, defibrillators or what else. 2013 , 35, 49-54	10
223	Blood pressure variability in chronic kidney disease patients. 2013 , 36, 58-62	12
222	Cardiorenal syndrome type 4: management. 2013 , 36, 200-9	15

221	Cardiorenal syndrome type 4: a review. 2013 , 3, 63-70		31
220	Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. 2013 , 84, 381-9		53
219	Prediction of in vivo atenolol removal by high-permeability hemodialysis based on an in vitro model. 2013 , 16, 657-64		3
218	Survival and heart failure therapy in chronic dialysis patients with heart failure and reduced left ventricular ejection fraction: an observational retrospective study. 2013 , 68, 51-7		12
217	Heart failure in patients with chronic kidney disease: a systematic integrative review. 2014 , 2014, 937398		85
216	Coronary artery calcification in chronic kidney disease: An update. 2014 , 6, 115-29		30
215	Pro: sympathetic renal denervation in hypertension and in chronic kidney disease. 2014 , 29, 1120-3		3
214	Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). 2014 , 29, 400-5		23
213	Der vulnerable Patient mit chronischer Niereninsuffizienz. 2014 , 09, 271-275		
212	What are the causes of the ill effects of chronic hemodialysis? Toward a reduction in the risk of electrolyte-related sudden death. 2014 , 27, 16-8		2
211	Of heart and kidney: a complicated love story. 2014 , 21, 840-6		9
210	Cardiovascular risk assessment before and after kidney transplantation. 2014 , 22, 153-62		37
209	Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation?. 2014 , 32, 1751-61		20
208	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. 2014 , 488-496		0
207	Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 537-8	15.1	19
206	Medication among patients with type 1 diabetes and predialytic renal disease. 2014 , 103, 510-5		
205	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 853-71	15.1	80
204	Consider specific co-morbidities and disease aetiology when treating hypertension in patients with chronic kidney disease. 2014 , 30, 60-64		

203	Cardiovascular disease in chronic kidney disease. 2014 , 3, 20-29	2
202	Assessment and management of hypertension in patients on dialysis. 2014 , 25, 1630-46	106
201	Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. 2014 , 29, 672-81	144
200	Risk of sudden cardiac death in chronic kidney disease. 2014 , 25, 222-31	24
199	The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. 2014 , 21, 480-8	33
198	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. 2014 , 383, 1831-43	250
197	Sudden cardiac death in haemodialysis patients: preventative options. 2014 , 19, 740-9	21
196	Dialysierbarkeit von ßBlockern und Mortalität. 2015 , 10, 318-319	
195	Management of Noncardiac Comorbidities in Chronic Heart Failure. 2015 , 33, 300-15	22
194	8.5 Ratschläge zur Abklärung und Betreuung von Patienten mit chronischer Nierenerkrankung. 2015 ,	
193	Moderator's view: Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients. 2015 , 30, 1443-8	20
192	Sudden cardiac death in end stage renal disease: unlocking the mystery. 2015 , 28, 133-41	5
191	Norepinephrine, left ventricular disorders and volume excess in ESRD. 2015 , 28, 729-37	4
190	Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review. 2015 , 17, 59	42
189	Prevention of Heart Failure in Patients with Chronic Kidney Disease. 2015 , 9, 1	1
188	Antihypertensive Medications in End-Stage Renal Disease. 2015 , 28, 330-6	15
187	ßBlocker dialyzability and mortality in older patients receiving hemodialysis. 2015 , 26, 987-96	64
186	Sudden cardiac death in CKD patients. 2015 , 47, 971-82	18

185	Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. 2015 , 3, 993-1003		20
184	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications. 2015 , 35, 388-96		37
183	Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. 2015 , 5, 254-66		110
182	Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis Patients. 2015 , 10, 1408-17		65
181	Management of Heart Failure. 2015 ,		1
180	The rationale and design of the Beta-blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study. 2015 , 20, 140-7		5
179	Chronic kidney disease and cardiovascular complications. 2015 , 20, 259-72		128
178	βBlockers in dialysis patients: a nephrocardiology perspective. 2015 , 26, 774-6		8
177	Approach to the Patient with Hypertensive Nephrosclerosis. 2015 , 455-469		
176	Chronic Kidney Disease and Heart Failure [A Nephrologic Approach. 2015 , 560-570		
175	The Challenges of Blood Pressure Control in Dialysis Patients. 2015 , 10, 34-59		2
174	Chronic Kidney Disease As a Potential Indication for Renal Denervation. 2016 , 7, 220		6
173	Hypertension Management in Transition: From CKD to ESRD. 2016 , 23, 255-61		7
172	Cardiorenal Syndrome in Western Countries: Epidemiology, Diagnosis and Management Approaches. 2017 , 2, 151-163		35
171	Cardiovascular complications in chronic dialysis patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2016 , 25, 536-544	3.5	22
170	Clearance of cardiovascular medications during hemodialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2016 , 25, 257-67	3.5	4
169	The heart and vascular system in dialysis. 2016 , 388, 276-84		148
168	A βBlocker Trial in Dialysis Patients: Is It Feasible and 'Worthwhile?'. 2016 , 67, 822-5		1

167	Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. 2016 , 12, 636-47	35
166	Multiphasic effects of blood pressure on survival in hemodialysis patients. 2016 , 90, 674-84	27
165	Pharmacotherapy of Hypertension in Chronic Dialysis Patients. 2016 , 11, 2062-2075	25
164	Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis. 2016 , 18, 125	4
163	Hypertension in the Dialysis Patient. 2016 , 133-166	
162	A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. 2016 , 10, 163-171	3
161	Management of hypertension for patients undergoing dialysis therapy. 2016 , 2,	5
160	Efficacy of loop diuretics in the management of undocumented patients with end-stage renal disease. 2016 , 34, 1552-5	3
159	Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 2016 , 4, 649-61	8
158	Effectiveness comparison of cardio-selective to non-selective β blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study. 2016 , 16, 60	10
157	Global challenges posed by the growth of end-stage renal disease. 2016 , 2,	47
156	Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. 2016 , 5,	18
155	Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. 2016 , 133, 518-36	108
154	Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment. 2016 , 30, 1-6	22
153	The β Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. 2016 , 67, 902-11	26
152	[Cardiac arrest in dialysis patients: Risk factors, preventive measures and management in 2015]. 2016 , 12, 6-17	1
151	Carvedilol: a review of its use in the management of heart failure. 2017 , 33, 147-152	3
150	Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. 2017 , 232, 12-23	44

149	Sudden Cardiac Death Among Hemodialysis Patients. 2017 , 69, 684-695		62
148	Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain. 2017 , 30, 203-212		15
147	Pathophysiology of the cardio-renal syndromes types 1-5: An update. 2017 , 69, 255-265		51
146	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). 2017 , 32, 620-640		79
145	Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease. 2017 , 37, 120-131		20
144	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). 2017 , 32, 657-676		35
143	Efficacy of antihistamines on mortality in patients receiving maintenance hemodialysis: an observational study using propensity score matching. 2017 , 32, 1195-1201		3
142	Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection-A Proof-of-Concept Study. 2017 , 2, 856-865		5
141	The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study. 2017 , 2, 665-675		2
140	Sudden Cardiac Death in CKD and ESKD: Risk Factors, Mechanisms, and Therapeutic Strategies. 2017 , 21-33		
139	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 2017 , 33, 1342-1433		330
138	Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors. 2017 , 30, 532-536		12
137	Blood Pressure of Maintenance Hemodialysis Patients in the Dalmatian Region of Croatia: Differences between Hospital and Out-of-Hospital Dialysis Centers. 2017 , 44, 110-121		1
136	Diagnosis and Management of Heart Failure in Long-Term Dialysis Patients. 2017 , 14, 404-409		4
135	Treatment of Hypertension in Light of the New Guidelines: Pharmacologic Approaches Using Combination Therapies. 2017 , 283-306		
134	Resistant Hypertension in Chronic Kidney Disease. 2017 ,		0
133	Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. <i>Medicine (United States)</i> , 2017 , 96, e5924	1.8	13
132	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. 2017 , 42, 1033-1044		5

131	The Clinical Problems of Hypertension Treatment in Hemodialysis Patients. <i>Current Vascular Pharmacology</i> , 2017 , 16, 54-60	33	10
130	What happens to the heart in chronic kidney disease?. 2017 , 47, 76-82		14
129	The Challenges of Blood Pressure Control in Dialysis Patients. 2017 , 603-626.e2		
128	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. 2017 , 47, 555-643		44
127	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. 2018 , 72, 728-744		33
126	-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. 2018 , 13, 604-611		18
125	Beta blockers in patients with end-stage renal disease-Evidence-based recommendations. 2018 , 31, 219-225		12
124	Hemodialysis-induced cardiovascular disease. 2018 , 31, 258-267		49
123	A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis. 2018 , 72, 337-348		24
122	Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease. 2018 , 355, 247-251		1
121	Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. 2018 , 38, 600-617		26
120	Cardiovascular Disease in Dialysis Patients. 2018 ,		0
119	The impact of chronic kidney disease on medication choice and pharmacologic management in patients with heart failure. 2018 , 11, 571-579		3
118	Use of Beta-Blockers on Maintenance Dialysis Patients and Ischemic Cerebral and Cardiovascular Deaths: An Examination Using Propensity Score. 2018 , 195, 120-130		2
117	Prevalence and Hypertension Treatment Schedule in Hemodialysis Patients and Renal Transplant Recipients in 2006 and 2014/2016. 2018 , 50, 1807-1812		1
116	Blood pressure control in conventional hemodialysis. 2018 , 31, 557-562		5
115	Hypertension and Chronic Kidney Disease. 2018 , 311-320		
114	Patient-Centered Approach for Hypertension Management in End-Stage Kidney Disease: Art or Science?. 2018 , 38, 355-368		

113	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). 2018 , 10,	19
112	Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease. 2018 , 15, 307-314	8
111	Heterogeneity in Outcomes Among β Blockers Elucidated by Intradialytic Data. 2018 , 72, 318-321	
110	DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. 2018 , 94, 589-598	15
109	Effect of statin on life prognosis in Japanese patients undergoing hemodialysis. 2019 , 14, e0224111	5
108	[Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure]. 2019 , 44, 611-629	1
107	Thinking Volume First: Developing a Multifaceted Systematic Approach to Volume Management in Hemodialysis. 2019 , 6, 2054358119879776	1
106	Antihypertensive Agents in the Dialysis Patient. 2019 , 21, 5	2
105	Evolving concepts in the pathogenesis of uraemic cardiomyopathy. 2019 , 15, 159-175	54
104	Treatment of Cardiorenal Syndrome. 2019 , 37, 267-273	8
103	Challenges in Assessing the Burden of Hospitalized Heart Failure in End-Stage Kidney Disease. 2019 , 25, 534-536	
102	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2019 , 95, 1304-1317	96
101	Effects of Beta-Blockers on Cardiovascular Events and Mortality in Dialysis Patients: A Systematic Review and Meta-Analysis. 2019 , 48, 51-59	8
100	Trends in In-Hospital Mortality, Length of Stay, Nonroutine Discharge, and Cost Among End-Stage Renal Disease Patients on Dialysis Hospitalized With Heart Failure (2001-2014). 2019 , 25, 524-533	4
99	Strategies for the Super-Aged Dialysis Population: Survival Benefits or Alternative Goals?. 2019 , 47 Suppl 2, 95-105	
98	Beta-blockers use from the general to the hemodialysis population. 2019 , 15, 71-76	2
97	Management of Hypertension in Chronic Kidney Disease. 2019 , 79, 365-379	75
96	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2893-2904	15.1 17

- 95 Heart Failure With Reduced Ejection Fraction and Renal Dysfunction: Beta-Blockers Do Not Disappoint. *Journal of the American College of Cardiology*, **2019**, 74, 2905-2907 15.1 2
- 94 Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study. **2019**, 34, 1216-1222 2
- 93 Acute Complications of Hemodialysis. **2019**, 411-426.e6
- 92 Hypertension in patients on dialysis: diagnosis, mechanisms, and management. **2019**, 41, 400-411 13
- 91 Sympathetic overactivity in dialysis patients-Underappreciated and clinically consequential. **2019**, 32, 255-265
- 90 Hypertensive Chronic Kidney Disease. **2019**, 62-72.e6
- 89 Cardiovascular Disease in Chronic Kidney Disease. **2019**, 176-193.e9
- 88 Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. **2020**, 60, 75-85 1
- 87 Cardiorenal Syndrome in Heart Failure. **2020**, 1
- 86 Chronic Kidney Disease and Heart Failure—Nephrologic Approach. **2020**, 883-897
- 85 Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study. *BMC Nephrology*, **2020**, 21, 413 2.7 2
- 84 Pooled RCTs: In patients with HF in sinus rhythm, β blockers reduced mortality at GFR ≥ 30 mL/min/1.73 m². **2020**, 172, JC38
- 83 Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. **2020**, 38, 1669-1681 17
- 82 The incidence and survival after in-hospital cardiopulmonary cerebral resuscitation in end-stage kidney disease patients: A nationwide population-based study. **2020**, 15, e0238029
- 81 Evaluation of management and factors associated with hypertension control in hemodialysis patients at a tertiary-care hospital in Pakistan. **2020**, 36, 396-403 2
- 80 The uraemic hypertensive patient: a therapeutic challenge-right you are (if you think so). **2020**, 22, L44-L48
- 79 Effect of carvedilol on arteriovenous graft primary patency. **2020**, 28, 765-774 1
- 78 Approach and Management of Hypertension After Kidney Transplantation. **2020**, 7, 229 18

77	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2020 , 97, 861-876	44
76	Pharmacological interventions for heart failure in people with chronic kidney disease. 2020 , 2, CD012466	3
75	Acute stunning effect of hemodialysis on myocardial performance: A three-dimensional speckle tracking echocardiographic study. 2020 , 44, 1081-1089	6
74	Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. 2020 , 21, 1219-1240	0
73	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. 2020 , 104, S11-S103	113
72	EBlocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. 2021 , 77, 704-712	2
71	Sudden cardiac death in dialysis patients: different causes and management strategies. 2021 , 36, 396-405	16
70	Better peridialytic blood pressure control using carvedilol in end stage renal disease patients on twice weekly maintenance hemodialysis. 2021 , 53, 1007-1014	0
69	Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 983-990	4-5 3
68	The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart. 2021 , 42, 1244-1253	7
67	Management of Heart Failure Patient with CKD. 2021 , 16, 1131-1139	2
66	Personalising heart failure management in CKD patients. 2021 ,	2
65	Baseline characteristics and outcomes of end-stage renal disease patients after in-hospital sudden cardiac arrest: a national perspective. 2021 , 1	1
64	Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes. 2021 , 8,	1
63	Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4. 2021 , 394, 2117-2128	1
62	Kidney Disease and Hypertension. 2007 , 607-619	6
61	Interface Between Renal Disease and Cardiovascular Illness. 2012 , 1934-1948	1
60	Development and validation of algorithms for heart failure patient care: a Delphi study. 2015 , 56, 217-23	1

59	Sympathetic Hyperactivity A Hidden Enemy in Chronic Kidney Disease Patients. 2007 , 27, 293-297		5
58	Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. 2012 , 7, e41281		107
57	Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease. 2018 , 14, 60-66		5
56	Left Ventricular Hypertrophy in Patients with Chronic Kidney Disease. 2014 , 26, 281-289		1
55	Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. 2013 , 80, 313-21		11
54	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. <i>Acta Cardiologica Sinica</i> , 2019 , 35, 244-283	1.1	31
53	Treatment of Hypertension in Patients with Renal Disease. 2007 , 647-657		
52	Management of Hypertension in Patients Receiving Dialysis. 2008 , 680-690		
51	Cardiovascular Complications of End-Stage Renal Disease. 2008 , 773-782		
50	Cardiovascular issues of dialysis patients referred for ultrasound examination of vascular access grafts. <i>Cor Et Vasa</i> , 2008 , 50, 287-291		0.3
49	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. 2009 , 499-505		
48	Kidney Disease and Medications. 2010 , 208-217		
47	Cardiomyopathy in Chronic Kidney Disease and in End-stage Renal Disease. 2010 , 175-187		
46	Heart failure in patients on dialysis. A review of the issue and proposed therapeutic algorithm. <i>Cor Et Vasa</i> , 2010 , 52, 229-233		0.3
45	Anemia and Cardiovascular Disease. 229-251		
44	Inhibition of the Renin-Angiotensin System and Cardiovascular Mortality in Chronic Hemodialysis Patients. <i>International Journal of Clinical Medicine</i> , 2011 , 02, 57-63		0.3
43	????. <i>Nihon Toseki Igakkai Zasshi</i> , 2011 , 44, 369-374		0.3
42	??. I. <i>Nihon Toseki Igakkai Zasshi</i> , 2011 , 44, 383-388		0.3

41	?? ??????????????????. <i>Nihon Toseki Igakkai Zasshi</i> , 2011 , 44, 419-425	0.3	
40	?? ???? II. ??????. <i>Nihon Toseki Igakkai Zasshi</i> , 2011 , 44, 363-368	0.3	
39	Diabetic Nephropathy. 2011 , 1411-1454		6
38	Síndrome cardio-renal: diagnóstico y tratamiento. <i>Medwave</i> , 2011 ,	2.5	
37	Sudden Cardiac Death and Dysrhythmia in Hemodialysis Patients. <i>Japanese Journal of Electrocardiology</i> , 2012 , 32, 321-326	0	
36	Pharmacogenomics of Cardiovascular Drugs. 98-126		
35	Sudden Cardiac Arrest in Chronic Kidney Disease. 2013 , 475-486		
34	Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new. <i>Journal of Clinical Investigation</i> , 2013 , 123, 542-3	15.9	10
33	Cardiovascular Issues and Renal Disease. 2014 , 355-374		
32	Sudden Cardiac Death and Arrhythmia in CKD. 2015 , 19-27		
31	Management of Non-cardiac Co-morbidities in Chronic Heart Failure. 2015 , 231-248		
30	Current status of peripheral artery disease in patients with end stage renal disease: Point of view of a cardiologist. <i>The Journal of Japanese Society of Limb Salvage and Podiatric Medicine</i> , 2015 , 7, 136-140	0	
29	Evaluation of catecholamines in erythrocytes in hemodialysis patients. 2016 , 51, 285-290		
28	Hypertension in Dialysis Patients: Clinical Epidemiology, Pathogenesis, Diagnosis, and Treatment. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018 , 383-417	0.1	
27	Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapy. 2020 , 107-120		
26	Antihypertensive Therapy in Patients Receiving Maintenance Hemodialysis: A Narrative Review of the Available Clinical-Trial Evidence. <i>Current Vascular Pharmacology</i> , 2021 , 19, 12-20	3.3	0
25	β-blockers in hemodialysis: simple questions, complicated answers. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 731-734	4.5	1
24	Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 198-207	3.5	0

23	Prevention and management of cardiovascular disease in kidney disease and kidney failure. 2022 , 207-223		
22	Treatment in Advanced Renal Disease in Type 1 and Type 2 Diabetes. 2006 , 419-436		
21	Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 20-29	1.7	
20	Cardiorenal Syndrome in Patients on Renal Replacement Therapy.		
19	Chronic Kidney Disease and Heart Failure-Everyday Diagnostic Challenges. <i>Diagnostics</i> , 2021 , 11,	3.8	0
18	Difference in Antihypertensive Medication Pattern in the First Year Compared to More than a Year of Maintenance Hemodialysis: A Northern India Tertiary Care Experience. <i>Annals of the National Academy of Medical Sciences (India)</i> ,	0.3	
17	Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.. <i>BMC Nephrology</i> , 2022 , 23, 9	2.7	3
16	Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	3
15	Beta-blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review.. <i>Kidney Medicine</i> , 2022 , 4, 100460	2.8	1
14	Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial.. <i>Medicine (United States)</i> , 2021 , 100, e28322	1.8	0
13	The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
12	Mechanism of carvedilol induced action potential and calcium alternans.. <i>Channels</i> , 2022 , 16, 97-112	3	0
11	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	1
10	Management of Heart Failure in Patients with Chronic Kidney Disease. 17,		0
9	The Challenges of Blood Pressure Control in Hemodialysis Patients. 2023 , 393-405		
8	Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. 2022 ,		0
7	Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. 2022 , 101509		1
6	General Management of the Hemodialysis Patient. 2022 , 34-47		0

- 5 Hypertension in Patients Receiving Dialysis: A Review of the Current Clinical Approach. ○
- 4 Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis. **2022**, 17, e0279680 ○
- 3 Deep Learning Using Electrocardiograms in Patients on Maintenance Dialysis. **2023**, 30, 61-68 ○
- 2 Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. **2023**, 20, 101-112 ○
- 1 Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. **2018**, 506-514.e1 ○